Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode

A multicenter study

Hiroshi Kunugi, Itsuro Ida, Toshimi Owashi, Mahito Kimura, Yumiko Inoue, Shin Nakagawa, Takafumi Yabana, Takako Urushibara, Rie Kanai, Masako Aihara, Naoya Yuuki, Tempei Otsubo, Akihiko Oshima, Koutaro Kudo, Takeshi Inoue, Yuji Kitaichi, Osamu Shirakawa, Koichi Isogawa, Haruo Nagayama, Kunitoshi Kamijima & 4 others Shinichiro Nanko, Shigenobu Kanba, Teruhiko Higuchi, Masahiko Mikuni

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

There is compelling evidence for the involvement of hypothalamic-pituitary- adrenal (HPA) axis abnormalities in depression. Growing evidence has suggested that the combined dexamethasone (DEX)/corticotropin-releasing hormone (CRH) test is highly sensitive to detect HPA axis abnormalities. We organized a multicenter study to assess the DEX/CRH test as a state-dependent marker for major depressive episode in the Japanese population. We conducted the DEX/CRH test in 61 inpatients with major depressive episode (Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV)) and 57 healthy subjects. In all, 35 patients were repeatedly assessed with the DEX/CRH test on admission and before discharge. The possible relationships between clinical variables and the DEX/ CRH test were also examined. Significantly enhanced pituitary- adrenocortical responses to the DEX/CRH test were observed in patients on admission compared with controls. Such abnormalities in patients were significantly reduced after treatment, particularly in those who underwent electroconvulsive therapy (ECT) in addition to pharmacotherapy. Age and female gender were associated with enhanced hormonal responses to the DEX/CRH test. Severity of depression correlated with DEX/CRH test results, although this was explained, at least in part, by a positive correlation between age and severity in our patients. Medication per se was unrelated to DEX/CRH test results. These results suggest that the DEX/CRH test is a sensitive state-dependent marker to monitor HPA axis abnormalities in major depressive episode during treatment. Restoration from HPA axis abnormalities occurred with clinical responses to treatment, particularly in depressed patients who underwent ECT.

Original languageEnglish
Pages (from-to)212-220
Number of pages9
JournalNeuropsychopharmacology
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 1 2006

Fingerprint

Corticotropin-Releasing Hormone
Dexamethasone
Multicenter Studies
Electroconvulsive Therapy
Diagnostic and Statistical Manual of Mental Disorders
Depression
Patient Admission
Inpatients
Healthy Volunteers
Therapeutics
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode : A multicenter study. / Kunugi, Hiroshi; Ida, Itsuro; Owashi, Toshimi; Kimura, Mahito; Inoue, Yumiko; Nakagawa, Shin; Yabana, Takafumi; Urushibara, Takako; Kanai, Rie; Aihara, Masako; Yuuki, Naoya; Otsubo, Tempei; Oshima, Akihiko; Kudo, Koutaro; Inoue, Takeshi; Kitaichi, Yuji; Shirakawa, Osamu; Isogawa, Koichi; Nagayama, Haruo; Kamijima, Kunitoshi; Nanko, Shinichiro; Kanba, Shigenobu; Higuchi, Teruhiko; Mikuni, Masahiko.

In: Neuropsychopharmacology, Vol. 31, No. 1, 01.01.2006, p. 212-220.

Research output: Contribution to journalArticle

Kunugi, H, Ida, I, Owashi, T, Kimura, M, Inoue, Y, Nakagawa, S, Yabana, T, Urushibara, T, Kanai, R, Aihara, M, Yuuki, N, Otsubo, T, Oshima, A, Kudo, K, Inoue, T, Kitaichi, Y, Shirakawa, O, Isogawa, K, Nagayama, H, Kamijima, K, Nanko, S, Kanba, S, Higuchi, T & Mikuni, M 2006, 'Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: A multicenter study', Neuropsychopharmacology, vol. 31, no. 1, pp. 212-220. https://doi.org/10.1038/sj.npp.1300868
Kunugi, Hiroshi ; Ida, Itsuro ; Owashi, Toshimi ; Kimura, Mahito ; Inoue, Yumiko ; Nakagawa, Shin ; Yabana, Takafumi ; Urushibara, Takako ; Kanai, Rie ; Aihara, Masako ; Yuuki, Naoya ; Otsubo, Tempei ; Oshima, Akihiko ; Kudo, Koutaro ; Inoue, Takeshi ; Kitaichi, Yuji ; Shirakawa, Osamu ; Isogawa, Koichi ; Nagayama, Haruo ; Kamijima, Kunitoshi ; Nanko, Shinichiro ; Kanba, Shigenobu ; Higuchi, Teruhiko ; Mikuni, Masahiko. / Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode : A multicenter study. In: Neuropsychopharmacology. 2006 ; Vol. 31, No. 1. pp. 212-220.
@article{02b39b34f1ec4b67bb9cf93f7fef7398,
title = "Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: A multicenter study",
abstract = "There is compelling evidence for the involvement of hypothalamic-pituitary- adrenal (HPA) axis abnormalities in depression. Growing evidence has suggested that the combined dexamethasone (DEX)/corticotropin-releasing hormone (CRH) test is highly sensitive to detect HPA axis abnormalities. We organized a multicenter study to assess the DEX/CRH test as a state-dependent marker for major depressive episode in the Japanese population. We conducted the DEX/CRH test in 61 inpatients with major depressive episode (Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV)) and 57 healthy subjects. In all, 35 patients were repeatedly assessed with the DEX/CRH test on admission and before discharge. The possible relationships between clinical variables and the DEX/ CRH test were also examined. Significantly enhanced pituitary- adrenocortical responses to the DEX/CRH test were observed in patients on admission compared with controls. Such abnormalities in patients were significantly reduced after treatment, particularly in those who underwent electroconvulsive therapy (ECT) in addition to pharmacotherapy. Age and female gender were associated with enhanced hormonal responses to the DEX/CRH test. Severity of depression correlated with DEX/CRH test results, although this was explained, at least in part, by a positive correlation between age and severity in our patients. Medication per se was unrelated to DEX/CRH test results. These results suggest that the DEX/CRH test is a sensitive state-dependent marker to monitor HPA axis abnormalities in major depressive episode during treatment. Restoration from HPA axis abnormalities occurred with clinical responses to treatment, particularly in depressed patients who underwent ECT.",
author = "Hiroshi Kunugi and Itsuro Ida and Toshimi Owashi and Mahito Kimura and Yumiko Inoue and Shin Nakagawa and Takafumi Yabana and Takako Urushibara and Rie Kanai and Masako Aihara and Naoya Yuuki and Tempei Otsubo and Akihiko Oshima and Koutaro Kudo and Takeshi Inoue and Yuji Kitaichi and Osamu Shirakawa and Koichi Isogawa and Haruo Nagayama and Kunitoshi Kamijima and Shinichiro Nanko and Shigenobu Kanba and Teruhiko Higuchi and Masahiko Mikuni",
year = "2006",
month = "1",
day = "1",
doi = "10.1038/sj.npp.1300868",
language = "English",
volume = "31",
pages = "212--220",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode

T2 - A multicenter study

AU - Kunugi, Hiroshi

AU - Ida, Itsuro

AU - Owashi, Toshimi

AU - Kimura, Mahito

AU - Inoue, Yumiko

AU - Nakagawa, Shin

AU - Yabana, Takafumi

AU - Urushibara, Takako

AU - Kanai, Rie

AU - Aihara, Masako

AU - Yuuki, Naoya

AU - Otsubo, Tempei

AU - Oshima, Akihiko

AU - Kudo, Koutaro

AU - Inoue, Takeshi

AU - Kitaichi, Yuji

AU - Shirakawa, Osamu

AU - Isogawa, Koichi

AU - Nagayama, Haruo

AU - Kamijima, Kunitoshi

AU - Nanko, Shinichiro

AU - Kanba, Shigenobu

AU - Higuchi, Teruhiko

AU - Mikuni, Masahiko

PY - 2006/1/1

Y1 - 2006/1/1

N2 - There is compelling evidence for the involvement of hypothalamic-pituitary- adrenal (HPA) axis abnormalities in depression. Growing evidence has suggested that the combined dexamethasone (DEX)/corticotropin-releasing hormone (CRH) test is highly sensitive to detect HPA axis abnormalities. We organized a multicenter study to assess the DEX/CRH test as a state-dependent marker for major depressive episode in the Japanese population. We conducted the DEX/CRH test in 61 inpatients with major depressive episode (Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV)) and 57 healthy subjects. In all, 35 patients were repeatedly assessed with the DEX/CRH test on admission and before discharge. The possible relationships between clinical variables and the DEX/ CRH test were also examined. Significantly enhanced pituitary- adrenocortical responses to the DEX/CRH test were observed in patients on admission compared with controls. Such abnormalities in patients were significantly reduced after treatment, particularly in those who underwent electroconvulsive therapy (ECT) in addition to pharmacotherapy. Age and female gender were associated with enhanced hormonal responses to the DEX/CRH test. Severity of depression correlated with DEX/CRH test results, although this was explained, at least in part, by a positive correlation between age and severity in our patients. Medication per se was unrelated to DEX/CRH test results. These results suggest that the DEX/CRH test is a sensitive state-dependent marker to monitor HPA axis abnormalities in major depressive episode during treatment. Restoration from HPA axis abnormalities occurred with clinical responses to treatment, particularly in depressed patients who underwent ECT.

AB - There is compelling evidence for the involvement of hypothalamic-pituitary- adrenal (HPA) axis abnormalities in depression. Growing evidence has suggested that the combined dexamethasone (DEX)/corticotropin-releasing hormone (CRH) test is highly sensitive to detect HPA axis abnormalities. We organized a multicenter study to assess the DEX/CRH test as a state-dependent marker for major depressive episode in the Japanese population. We conducted the DEX/CRH test in 61 inpatients with major depressive episode (Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV)) and 57 healthy subjects. In all, 35 patients were repeatedly assessed with the DEX/CRH test on admission and before discharge. The possible relationships between clinical variables and the DEX/ CRH test were also examined. Significantly enhanced pituitary- adrenocortical responses to the DEX/CRH test were observed in patients on admission compared with controls. Such abnormalities in patients were significantly reduced after treatment, particularly in those who underwent electroconvulsive therapy (ECT) in addition to pharmacotherapy. Age and female gender were associated with enhanced hormonal responses to the DEX/CRH test. Severity of depression correlated with DEX/CRH test results, although this was explained, at least in part, by a positive correlation between age and severity in our patients. Medication per se was unrelated to DEX/CRH test results. These results suggest that the DEX/CRH test is a sensitive state-dependent marker to monitor HPA axis abnormalities in major depressive episode during treatment. Restoration from HPA axis abnormalities occurred with clinical responses to treatment, particularly in depressed patients who underwent ECT.

UR - http://www.scopus.com/inward/record.url?scp=32844462857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844462857&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300868

DO - 10.1038/sj.npp.1300868

M3 - Article

VL - 31

SP - 212

EP - 220

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -